1 not yet recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 1, Recruiting 1, Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Xiangdong Cheng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Combined With SOX Used in Theperioperative Treatment QL1706 combined with SOX - Gastric Cancers, Esophagogastric Junction Cancers | Phase 1 / Phase 2 | Recruiting | Xiangdong Cheng | 54 | 2025-03-21 | 2025-06-17 |
| Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment. Tislelizumab, SOX/XELOX - Gastric Cancer | Phase 2 | Not yet recruiting | Xiangdong Cheng | 134 | 2024-04-25 | 2024-04-19 |
| Nivolumab Combined With SOX Used in the Perioperative Treatment nivolumab combined with SOX - Immune Suppression, Gastric Cancer | Phase 2 | Unknown | Xiangdong Cheng | 46 | 2022-11-03 | 2024-07-09 |
tislelizumab (1)
China (3)
Cheng Xiangdong (1)